Fondaparinux: pharmacology and clinical experience in cardiovascular medicine.
Fondaparinux is a synthetic, five-saccharide chain, AT-dependent, anti-FXa agent. Studies showed that fondaparinux acts in prevention and treatment of venous thromboembolism and in ischemic heart disease, without significant bleeding risk. The drug inhibits thrombin generation, has long half-life and can be administered once-daily without laboratory monitoring. It may be used in HIT treatment.
Toschi
V
V
Department of Hematology, and Blood Transfusion, Ospedale San Carlo Borromeo, Via Pio II, 3-20153 Milano, Italy. vincenzo.toschi1@virgilio.it
Lettino
M
M
D000925:Anticoagulants / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D005170:Factor X / Q000037:antagonists & inhibitors; D000077425:Fondaparinux; D006801:Humans; D011134:Polysaccharides / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use
D000925:Anticoagulants; D011134:Polysaccharides; D005170:Factor X; D000077425:Fondaparinux